Literature DB >> 21160771

Positron emission tomography's changing significance in the treatment of esophageal cancer.

Shane Hopkins1, Gary Yang.   

Abstract

Incidence of esophageal cancer has been rising, and Positron Emission Tomography (PET) is one tool that has shown utility and promise as a tool for staging, treatment response, and prognosis. PET delivery has evolved over time and is now frequently registered with a CT scan at the time of acquisition. However, resolution and confounders such as post-treatment radiation changes may limit clinical utility. PET has been shown to be helpful in staging, especially in evaluating for distant metastases. PET acquired after chemoradiation may give important prognostic information that can guide additional treatment decisions. Studies have had substantial variability in recommendations for the timing and manner of using PET for this purpose, and additional study is needed.

Entities:  

Keywords:  Esophageal cancer; Positron emission tomography; Staging

Year:  2009        PMID: 21160771      PMCID: PMC2999084          DOI: 10.4251/wjgo.v1.i1.34

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  22 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

2.  Attenuation correction of PET images with respiration-averaged CT images in PET/CT.

Authors:  Tinsu Pan; Osama Mawlawi; Sadek A Nehmeh; Yusuf E Erdi; Dershan Luo; Hui H Liu; Richard Castillo; Radhe Mohan; Zhongxing Liao; H A Macapinlac
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

5.  Proposed revision of the staging classification for esophageal cancer.

Authors:  R J Korst; V W Rusch; E Venkatraman; M S Bains; M E Burt; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

Review 6.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 7.  PET/CT of esophageal cancer: its role in clinical management.

Authors:  John F Bruzzi; Reginald F Munden; Mylene T Truong; Edith M Marom; Bradley S Sabloff; Gregory W Gladish; Revathy B Iyer; Tin-Su Pan; Homer A Macapinlac; Jeremy J Erasmus
Journal:  Radiographics       Date:  2007 Nov-Dec       Impact factor: 5.333

8.  Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?

Authors:  James M McLoughlin; Marcovalerio Melis; Erin M Siegel; E Michelle Dean; Jill M Weber; Jeannie Chern; Melanie Elliott; Scott T Kelley; Richard C Karl
Journal:  J Am Coll Surg       Date:  2008-05       Impact factor: 6.113

9.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

Authors:  Robert J Downey; Tim Akhurst; David Ilson; Robert Ginsberg; Manjit S Bains; Mithat Gonen; Heng Koong; Marc Gollub; Bruce D Minsky; Maureen Zakowski; Alan Turnbull; Steven M Larson; Valerie Rusch
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544

10.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.